Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and EUSA Pharma Inc. today announced that the companies have signed a definitive agreement under which Jazz Pharmaceuticals has agreed to acquire EUSA Pharma, a privately-held, specialty pharmaceutical company with headquarters in the United States and United Kingdom, for $650 million in cash¹ and a potential $50 million milestone payable in cash based upon its lead product, Erwinaze^™ (asparaginase Erwinia chrysanthemi), achieving a specified U.S. net sales target in 2013.

Data presented at the International Liver Disease Meeting demonstrated that the ALFApump System significantly decreases the need for Large Volume Paracentesis and can reduce hospital visits.

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactivebiomaterial combination products for trauma, wound and spinal indications has signed a license and development agreement with Synthes, Inc. a leading global medical device company.

Sequana Medical announced today that its ALFApump®System has received German Neue Untersuchungs und Behandlungsmethode (NUB) approval which allows participating hospitals to receive reimbursement for innovative new products. Sequana Medical’s ALFApump System is a fully implantable pump system designed to remove excess abdominal fluid, known as ascites, that collects in patients suffering from liver cirrhosis.